PT  - JOURNAL ARTICLE
AU  - Eric Toussirot
AU  - Martin Michaud
AU  - Daniel Wendling
AU  - Valérie Devauchelle
TI  - Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica
AID  - 10.3899/jrheum.210455
DP  - 2021 Sep 15
TA  - The Journal of Rheumatology
PG  - jrheum.210455
4099  - http://www.jrheum.org/content/early/2021/09/13/jrheum.210455.short
4100  - http://www.jrheum.org/content/early/2021/09/13/jrheum.210455.full
AB  - Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR).1 Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX).1